TECTONIC THERAPEUTIC, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
TECTONIC THERAPEUTIC, INC. (TECX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $3.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $3.73M.
- TECTONIC THERAPEUTIC, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00.
- TECTONIC THERAPEUTIC, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $757.00K.
- TECTONIC THERAPEUTIC, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.73M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $3.73M 10-Q · filed 2026-05-07 | ||
| 2025-12-31 | $757.00K 10-K · filed 2026-02-26 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |